Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA
Effectiveness of Bethanechol Chloride and Early Bladder Training for Prevention of Bladder Dysfunction After Radical Hysterectomy in Cervical Cancer Stage IB - IIA
Compare the effectiveness of bethanechol chloride and early bladder training for prevention
 of bladder dysfunction after radical hysterectomy in cervical cancer stage IB - IIA.
Cervical cancer is the third most common cancer in women worldwide, after breast and
 colorectal cancer. Molecular biology has firmly established a causal relationship between
 persistent infection with high risk human papilloma virus (HPV) genotypes and cervical
 cancer.

 Cervical cancer stage IB1 and selected IIA 1 lesions without extensive vaginal involvement
 can be treated with either RH and pelvic lymph node dissection (PLD) or primary
 chemoradiation.

 Bladder dysfunction is the most common complication after radical hysterectomy. The incidence
 is approximate 10-80 %. Management of bladder dysfunction is continuous urethral
 catheterization or clean intermittent self-catheterization. Prolonged urethral
 catheterization may increase the risk of urinary tract infection.

 Early postoperative bladder training that consist of a scheduled clamping trans-urethral
 catheter every 3 h and unclamping trans-urethral catheter 15 min during the entire day.

 Bethanechol chloride is a cholinergic drug and may enhance the detrusor muscle contraction,
 resulting in higher maximum flow rate, and lower postvoid residual urine.

 This study was conducted to compare the effectiveness of bethanechol chloride and early
 bladder training for prevention of bladder dysfunction after radical hysterectomy in cervical
 cancer stage IB - IIA.
Inclusion Criteria:

 -  Women with cervical cancer stage IB - IIA underwent standard type III radical
 hysterectomy, both open and laparoscopic approach

 -  Patient aged 20 - 65 years

 -  Patient able to give free and informed consent and who agrees to participate be
 signing the consent form

 Exclusion Criteria:

 -  Patient who had an allergic reaction to bethanechol chloride

 -  Patient who had neurogenic bladder